VistaGen Therapeutics

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system disorders. Its portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder, PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101, which the company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia, and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

VistaGen Therapeutics reports Q1 loss, focuses on FDA approval

VistaGen Therapeutics faces financial challenges with increased expenses but shows strength in its innovative drug candidates targeting mental health disorders. The company's opportunities lie in FDA approval for fasedienol and market expansion for its pherine drug candidates.

VistaGen reports positive trial results and financial stability in Q2

VistaGen Therapeutics showcased positive trial results and financial stability, emphasizing the potential of their pherine pipeline to create value and improve lives.
While facing challenges such as increased expenses and operational concerns, the company's commitment to advancing treatments presents opportunities for growth and market expansion.
Analyst interest in study details and timelines reflects investor confidence in VistaGen's research programs and potential market impact.
Overall, VistaGen's Q2 performance highlights progress in lead programs and a solid financial foundation for future growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. (NASDAQ: VTGN) a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Thursday, August 11, 2022, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report financial results for its fiscal year 2023 first quarter ended June 30, 202

VistaGen Therapeutics to Report Fiscal Year 2023 First Quarter Financial Results on August 11, 2022

Geovax Labs

Tonix Pharmaceuticals Hld

Here's what you need to know about trading penny stocks on July 26th The post What to Know About Buying Penny Stocks on July 26th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on July 26th

AMTD International Inc

Faraday Future Intelligent Electric

Check these tips out for trading penny stocks in August The post What to Know About Trading Penny Stocks in August  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Trading Penny Stocks in August

VistaGen Therapeutics (VTGN) stock is falling hard on Friday after the company reported poor results from a Phase 3 study. The post VistaGen Therapeutics (VTGN) Stock Plunges on Disappointing Clinical Data appeared first on InvestorPlace.

VistaGen Therapeutics (VTGN) Stock Plunges on Disappointing Clinical Data

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced topline results from its PALISADE-1 Phase 3 clinical trial of PH94B for the acute treatment of anxiety in adults with social anxiety disorder. PH94B did not achieve its primary e

VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--VistaGen's CEO will join U.S. Surgeon General, Vice Admiral Vivek H. Murthy at the Concordia Summit to discuss the ongoing mental health crisis.

VistaGen CEO Joins U.S. Surgeon General to Discuss Mental Health Crisis in America at the 2022 Concordia Americas Summit

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #PH94B--VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today announced that Chief Executive Officer Shawn Singh will participate in a panel discussing unmet needs and novel therapies in neuropsychiatry at the William Blair Biotech Focus Conference on

VistaGen to Participate at William Blair Biotech Focus Conference 2022

VistaGen Therapeutics, Inc. (NASDAQ:VTGN ) Q4 2022 Earnings Conference Call June 23, 2022 5:00 PM ET Company Participants Mark Flather - Vice President of Investor Relations Shawn Singh - Chief Executive Officer Jerrold Dotson - Vice President, Chief Financial Officer and Secretary Mark Smith - Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies LLC Lachlan Hanbury-Brown - William Blair & Company, LLC Luke Herrmann - Robert W. Baird & Co. Michael Okunewitch - Maxim Group LLC Operator Greetings, welcome to the VistaGen Therapeutics' 2022 Fiscal Year-End Results Conference Call.

VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q4 2022 Results - Earnings Call Transcript

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -33.33% and 88.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

VistaGen Therapeutics, Inc. (VTGN) Reports Q4 Loss, Misses Revenue Estimates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update

VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #VistaGen--VistaGen announces completion of PALISADE-1 Phase 3 clinical trial of PH94B for the acute treatment of anxiety in adults with social anxiety disorder

VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. (NASDAQ: VTGN) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, today announced it will host a conference call and webcast on Thursday, June 23, 2022, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report its financial results for fiscal year 2022 ending on March

VistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022

SOUTH SAN FRANCISCO--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today announced that the clinical trial abstract for its exploratory Phase 2A clinical study in adjustment disorder with anxiety (AjDA) for PH94B, its investigational rapid-onset pherine nasal spray with

VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting

Chembio Diagnostics

Enservco

Which penny stocks are you watching in June? The post Hot Penny Stocks For Your Buy List This Month?

Hot Penny Stocks For Your Buy List This Month? 3 to Watch

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, today announced that Shawn Singh, Chief Executive Officer, will participate in the following upcoming investor conferences in June. Management will be available for one-on-one meetings during these confere

VistaGen to Participate in Upcoming June Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, announced today a key regulatory update on its PALISADE Phase 3 Program for PH94B for the acute treatment of anxiety in adults with social anxiety disorder (SAD). The U.S. Food and Drug Administration (FDA

VistaGen Announces Key Regulatory Update on PH94B for the Acute Treatment of Social Anxiety Disorder

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today announced the appointment of Reid Adler as its Chief Legal Officer. Adler will oversee VistaGen's legal affairs and provide strategic guidance to its Executive Team and Board of Directors. “

VistaGen Appoints Reid Adler as Chief Legal Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen) a late clinical-stage, central nervous system (CNS) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, announced that researchers will present preclinical data supporting the differentiated mechanism of action (MOA) for VistaGen's lead product candidate, PH94B, at two upcoming major scientific cong

VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses

SOUTH SAN FRANCISCO, Calif. & SHANGHAI--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen) and AffaMed Therapeutics (AffaMed) today announced they have completed regulatory preparations to initiate PALISADE Global, a Phase 3 clinical trial to evaluate the efficacy, safety, and tolerability of VistaGen's PH94B (referred to by AffaMed as AM005) for the acute treatment of anxiety in adults with social anxiety disorder (SAD), in the U.S. and China. The primary purpose of PALISAD

VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, neuro-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that Chief Executive Officer Shawn Singh will participate in a fireside chat with Maxim Analyst Jason McCarthy, Ph.D., on Monday, March 28, 2022, at 2:00 p.m. Pacific Time during the Maxim Group 2022 Virtual Growth Conference.

VistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth Conference

VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q3 2022 Results - Earnings Call Transcript

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 37.50% and 8.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Tops Revenue Estimates

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) --   VistaGen Therapeutics, Inc . (Nasdaq: VTGN), a company developing therapeutics to transform the treatment paradigm for patients suffering from anxiety, depression and other central nervous system (CNS) disorders, today reported results for its third fiscal quarter ended December 31, 2021 and provided a corporate update.

VistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders, will host a conference call and webcast on Thursday, February 10, 2022 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report its financial results for its fiscal year 2022 third quarter ended December 31, 2021 and provide a review of recent accomplishments and anticipated upcoming milestones.

News for VistaGen Therapeutics Stock (VTGN)